PhRMA

Today, we launched a new campaign to highlight how the 340B hospital markup program is a goldmine for big nonprofit hospital systems. With no rules or transparency, hospitals can spend on luxury perks while patients face higher bills. Washington needs to fix 340B!

Nearly 9 in 10 Americans say if they get seriously ill – they want to be in the U.S. for treatment. While we continue to push for patients to be able to get the medicines they are prescribed, it’s important that we maintain the leadership in medical innovation that benefits every American. ow.ly/SgAM50Z5z3u

Global competition in biopharmaceutical innovation is accelerating. Countries like China are investing strategically and expanding R&D to lead in areas like oncology and advanced therapies. The U.S. must stay focused on policies that ensure we continue to lead. #InvestInAmericaForum #cnbcevents

This National Cancer Research Month, we’re reminded that smart policies and sustained investment have made America the global leader in cancer research. Maintaining this important leadership is not guaranteed. Let’s continue to bring next-generation cancer treatments to American patients. ow.ly/QpAO50Z5gR8

Illinois tax-exempt hospitals are exploiting the federal 340B program for profit, but aren't required to disclose what they earn, where that money goes or how it affects patients, employers and taxpayers. Read more: ow.ly/iHmc50Z4R35

58% of insured Americans managing a mental health condition are concerned their insurance company is going to deny their future care. As Mental Health Awareness Month comes to a close, we’re reminded of the important work to be done to increase access to care. ow.ly/GUQn50Z4QVl

In other high-income countries, patients wait 33 months for new medicines, on average, while U.S. patients wait about 3. Policy choices matter in getting patients new medicines.

Patients like Fred rely on medicines prescribed by their doctors to treat their conditions, but finding ways to afford this medicine can often feel overwhelming, with no clear place to start. America’s Medicines can be that first step for patients to explore options – and it’s free and confidential. Share this and help Fred spread the word!

This Memorial Day, we honor those who made the ultimate sacrifice for our country. Their legacy of service inspires our commitment to strengthening American leadership and security for all.

Immunotherapy is transforming how we fight cancer. In the early 2000s, this approach was still emerging, with only a handful of approved treatments. Today, breakthroughs like CAR-T therapies, immune checkpoint inhibitors and therapeutic vaccines are redefining cancer care. Since 2010, more than 30 immunotherapy treatments have been approved across 25 cancer types, with over 1,000 more in clinical trials. This progress is helping extend lives and bringing new hope to patients and families. ow.ly/SLYr50Z2Wmc

Mental health is health. Nearly 1 in 4 adults and more than 30% of young adults experienced a mental health condition in the past year, yet too many still go without care. Medicines and behavioral therapy can help improve outcomes for people living with mental health conditions. This #MentalHealthAwarenessMonth, we must continue working to reduce stigma and support timely access to effective care. ow.ly/6xAe50Z3i1s

“The insurance companies are becoming our doctors.” @CBSNews highlights a growing problem: 70% of patients face a rejection on their initial attempt to fill brand prescriptions. Patients deserve better. The latest: ow.ly/a51j50Z3i3H

May is Hepatitis Awareness Month, a time to highlight what evidence-based data continues to show: that the hepatitis B vaccine at birth protects babies from serious illness and lifelong health complications.

Today is Clinical Trials Day, and we celebrate the theme of Research Rising. Clinical trials are the bridge between a laboratory breakthrough and a life saving treatment. We recognize the researchers and patient volunteers who make progress possible.

Companies like @NovartisUS are making major investments in the U.S. – and it’s paying off. These commitments, like Novartis’ ongoing $23B investment and new manufacturing hub in North Carolina, are driving more jobs, more cures and more hope – right here at home.

Here’s how MFN price controls would hurt patients and workers: • 💸 Drain billions from U.S. research, manufacturing, and medical innovation • 🧬 Fewer new medicines for serious and life‑threatening conditions • 👷‍♂️📉 Millions of American jobs and retirement savings at risk • 🌍 Hand global leadership in innovation to China • 🚫💊 Import foreign pricing systems that delay or deny patient access 🚨 Real affordability means taking on middlemen and ending foreign free‑riding—not doubling down on price controls that don’t fix the problem.

ICYMI: New @FoxBusiness and @FoxNews reporting is putting a national spotlight on growing concerns around the 340B program. Read our blog to catch up on all the coverage ⬇️ ow.ly/XMya50Z0nYQ

A program created to help vulnerable patients is facing growing questions about transparency, accountability and where 340B profits are actually going. This @FoxBusiness segment highlights why policymakers and patients alike are taking a closer look at the program.

Dolores is one of thousands of individuals who have been cured of Hepatitis C. This Hepatitis Awareness Month, we recognize the impact of medical innovation and the importance of continued research to support the development of future treatments and cures.

MFN ties U.S. drug prices to other countries—but won’t guarantee lower costs. Insurers still control coverage, access, and what patients pay. Real affordability means fixing the system—not just setting prices. ow.ly/OHjn50YZzw5

Innovation was front and center this week as 26 biopharmaceutical researchers from 15 companies met with 70 California lawmakers to advocate for policies that help bring life-saving treatments to patients.